GlassScriptPhysician profile
Corryn M Della Flora
NPI 1740954551
$3,888.15
in general payments reported to CMS, 2019-2025
19 companies · $1,721 in 2025
The $1,721 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $494 · 2023: $736 · 2024: $937 · 2025: $1,721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,394.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $825.47 | 2024-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Boston Scientific Corporation | $683.35 | 2022-2025 | Watchman Flx, General - Therapies |
| Abbott Laboratories | $663.33 | 2023-2025 | Aveir, Jot Dx, Cardiomems |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $411.65 | 2022-2025 | Lifevest |
| Kestra Medical Technology Services, INC. | $256.24 | 2024-2025 | Assure Wcd |
| Biotronik INC. | $168.25 | 2023-2025 | Acticor 7 Vr-T Dx, Edora 8 Dr-T, Selectra |
| Edwards Lifesciences Corporation | $157.50 | 2022 | |
| Impulse Dynamics (USA) INC. | $153.80 | 2023 | Optimizer |
| Medtronic, INC. | $129.34 | 2022-2025 | Linq II, Cardioinsight |
| Janssen Pharmaceuticals, INC | $86.61 | 2023 | Xarelto |
| Cvrx, INC. | $81.37 | 2025 | Barostim Neo System |
| Kiniksa Pharmaceuticals International, Plc | $67.29 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $60.64 | 2025 | Amvuttra |
| Abiomed | $40.81 | 2025 | |
| Convatec INC. | $37.28 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $22.17 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $15.65 | 2022 | |
| Pfizer INC. | $14.58 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $12.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corryn Della Flora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.